Biocon Biologics is a fully integrated biosimilars enterprise uniquely equipped to serve patients worldwide.
Empowered by our unique lab-to-patient model and global scale, we advance innovation in biologics to address the world’s most pressing health challenges.
A fully integrated, global biosimilars enterprise
From lab to market
Capabilities
Powered by science and advanced technologies, we harness our deep expertise and highly skilled talent to create innovative solutions that put patients at the center of everything we do.
Products
We are addressing unmet medical needs and improving healthcare outcomes for patients in 120+ countries around the world.
Our Key Milestones
Kirsty is approved by the U.S. FDA as the first and only interchangeable rapid-acting insulin aspart.
Yesafili, biosimilar aflibercept, becomes the 10th biosimilar to be commercialized worldwide by Biocon Biologics.
Biocon Biologics consolidates acquired business operations across 120+ countries, and surpasses the USD 1 billion annual revenue mark.
Biocon Biologics successfully completes its multi billion-dollar acquisition of Viatris’ global biosimilars business.
Semglee, biosimilar Insulin Glargine, receives a historic U.S. approval as the world’s first ‘interchangeable’ biosimilar product.
Biocon’s Biosimilars business is consolidated under an independent entity – Biocon Biologics Limited – with its dedicated management.
Fulphila becomes the first biosimilar Pegfilgrastim to be approved in the U.S.
Ogivri becomes the first biosimilar Trastuzumab to be approved in the U.S.
CANMAb is launched in India the world’s first biosimilar Trastuzumab
Responsibility
At Biocon Biologics, we are deeply committed to inclusion, sustainability and driving positive social and environmentally sustainable impact for a healthier world.
On X
;
AI is accelerating a future where technology transcends the lab to solve society’s most complex challenges. At Google, success means ensuring this tech becomes a force for human progress across healthcare, agriculture, education and beyond.
At the #AIImpactSummit2026, James
@kiranshaw is Founder and Executive Chairperson of @Bioconlimited, a leading biopharmaceutical company based in India 💊
A pioneer of India’s biotechnology sector, she has led major advances in affordable biologics for cancer, diabetes and autoimmune diseases.
Congratulations to our new Honorary Fellows who have been elected for their outstanding contributions across health and science, driving innovation and improving lives around the world 🎉
Read more: https://bit.ly/46Klid7
And scroll to learn about our new Honorary Fellows 🧵
At @BioAsiaOfficial 2026, Biocon Biologics’ CEO & Managing Director, Mr. Shreehas Tambe, joined global industry leaders at the CEO Conclave – “Future of Pharma & Biotech (’26–’30)” to discuss whether India is at a true inflection point in its pharma journey.
As India looks to
Come meet @kiranshaw at #SYNAPSE, the world’s most thought-provoking science & tech society conference, 21–22 Feb.
She’s a pioneer of Indian biotechnology. The founder of Biocon. The woman who built India’s first globally respected biopharma company — starting in 1978 with
At The Times Group’s ET Now Global Business Summit 2026, co-powered by Spark Capital and @bennettuniv, Shreehas Tambe, CEO & Managing Director of Biocon Biologics, shares his optimism about India’s evolving biotech landscape.
He speaks of the strong policy momentum, greater
